CAR-T, Chimeric Antigen Receptor T-Cell Immunotherapy, is the most effective treatment of malignant tumors. Similar to other immunotherapy, its basic principle is to remove cancer cells in the use of the patient’s own immuneRead More…

On March 29, 2017, Novartis announced that the US FDA has issued a priority review for its CAR-T therapy CTL019 (tisagenlecleucel-T) biologics licensing application. The indications of CTL019 was recurrent or refractory B-cellRead More…